SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HMSC- A simple breast cancer screening device

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: FCC who wrote (70)3/4/1998 4:51:00 AM
From: (no name provided)  Read Replies (2) of 246
 
Dear FCC,

A couple of your points are wrong.

"1. The reason that the product is not reimbursed at this time is because it had come to the
market first. A OB-GYN friend of mine told me this fact. By the way Traveller's insurance comp.
owns a stake in HMSC."

The product is not reimbursed because it was decided by HCFA back in the mid-1980s that breast thermography was worthless and it withdrew reimbursement at that time.

"2.This product was never meant to replace mammograms, but to supplement them. This
technology is more sensitive than mammos, and palpation of the breast by the doctor. This
product is meant to be the earliest detection device for breast cancer, is they find a developing
tumor the pt has a greater chance for survival."

This is simply untrue. The BreastAlert device has undergone several clinical trials according to HMSC prospectus. It is less sensitive than mammography of the early 1980s. In addition, it has higher false positive rate.

"3. The product cost only $40. Very inexpensive as compared to other tests. The doctors are
charged $25 and make a small profit."

I'll give you this one.

"4. Any doctor who doesnt offer this test,even if it doesn't work for all patients will one day get
a letter from the lawyers office wondering why their client was not given the opportunity to
possibly catch the malignancy at an earlier reversible stage."

There is absolutely no data to support that BreastAlert can detect malignancy at an earlier stage than palpation or mammography.

"5. Patient has nothing to lose, to try a painless, radiation less, inexpensive, speedy test. The time that the women must wait to here results from mammos seems like an eternity."

The patient does have something to lose (other than money). Due to the high false positive rate, there will uncertainty in a large number of users.

"6. No one knows how well this product works, that's why they are doing the clinical trials.
They have made changes in the product before shipping. The reason for the delay was that
the product gave a false reading if it was shipped to very warm climate. That has all been
rectified."

Clinical trials have been done. Read the prospectus.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext